作者
Peter W Szlosarek, Jeremy P Steele, Luke Nolan, David Gilligan, Paul Taylor, James Spicer, Michael Lind, Sankhasuvra Mitra, Jonathan Shamash, Melissa M Phillips, Phuong Luong, Sarah Payne, Paul Hillman, Stephen Ellis, Teresa Szyszko, Gairin Dancey, Lee Butcher, Stephan Beck, Norbert E Avril, Jim Thomson, Amanda Johnston, Marianne Tomsa, Cheryl Lawrence, Peter Schmid, Timothy Crook, Bor-Wen Wu, John S Bomalaski, Nicholas Lemoine, Michael T Sheaff, Robin M Rudd, Dean Fennell, Allan Hackshaw
发表日期
2017/1/1
期刊
JAMA oncology
卷号
3
期号
1
页码范围
58-66
出版商
American Medical Association
简介
Importance
Preclinical studies show that arginine deprivation is synthetically lethal in argininosuccinate synthetase 1 (ASS1)-negative cancers, including mesothelioma. The role of the arginine-lowering agent pegylated arginine deiminase (ADI-PEG20) has not been evaluated in a randomized and biomarker-driven study among patients with cancer.
Objective
To assess the clinical impact of arginine depletion in patients with ASS1-deficient malignant pleural mesothelioma.
Design, Setting, and Participants
A multicenter phase 2 randomized clinical trial, the Arginine Deiminase and Mesothelioma (ADAM) study, was conducted between March 2, 2011, and May 21, 2013, at 8 academic cancer centers. Immunohistochemical screening of 201 patients (2011-2013) identified 68 with advanced ASS1-deficient malignant pleural mesothelioma.
Interventions
Randomization 2:1 to arginine deprivation (ADI-PEG20, 36.8 mg/m2 …
学术搜索中的文章
PW Szlosarek, JP Steele, L Nolan, D Gilligan, P Taylor… - JAMA oncology, 2017